Objectives :
The laboratory establishes and characterizes tumor models of in vitro and/or in vivo resistance to monoclonal antibodies for the development of new therapeutic treatments (either in combination or as monotherapy). These models are developed in syngeneic mice as well as through xenografts.
Research themes :
– Studying the mechanisms of action of monoclonal antibodies targeting cancer cells as well as mechanisms of resistance to these biomolecules.
– Optimizing treatment with monoclonal antibodies in patients with hematologic disorders or solid tumors.
– Developing new therapeutic approaches: immuno-adjuvants, new antibodies (including those with high DAR immunoconjugates).
Explore our available mouse models (drug resistant, immuno-competent, or immuno-deficient strains) to investigate lymphoma biology and identify novel drug targets.
3D Bioprinting allows the precise creation of complex tissue-like structures using cells and biomaterials. In oncology, it enables modeling of the tumor microenvironment to study cancer mechanisms and test new therapies.